CORDIS
EU research results

CORDIS

English EN
Collaborative Oncological Gene-environment Study

Collaborative Oncological Gene-environment Study

Objective

The overarching goal of COGS is to identify individuals with an increased risk of breast, ovary and prostate cancer. Furthermore, we will evaluate the effect of inherited genetic variation on tumour characteristics and clinical outcome. We will do this through quantifying the role of genetic and environmental/lifestyle risk in the largest data set ever generated. In all, we will include over 200,000 individuals in the COGS project. We will use detailed knowledge of the architecture of genetic susceptibility and interactions with environmental/lifestyle factors which will result in much more accurate individual risk prediction and improved intervention strategies. We are taking advantage of a unique possibility by incorporating seven existing consortia into one large project – COGS. Members of these consortia have collaborated successfully over the past years and results have been presented in world leading scientific journals such as Nature, Nature Genetics and Journal of the National Cancer Institute. These papers reflect that collaboration has been ongoing and that is has so far been very successful. We will also build on an existing European Commission project, TRANSBIG, thus adding value to already spent money. Results generated through COGS will lead to an improved understanding of the biological processes that underlie carcinogenesis, that in turn could guide new therapeutic strategies. Results will also lead to the development of new tests for risk prediction for breast, ovarian and prostate cancer.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 301 573,17

Administrative Contact

Agneta Haeggstroem (Ms.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 3 796 030,40

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

Australia

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

EU Contribution

€ 545 487,25

FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

Spain

EU Contribution

€ 2 300 650,68

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 201 534

HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ

Finland

EU Contribution

€ 201 471,60

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 1 087 739,60

FOUNDATION FOR GENOMICS & POPULATION HEALTH

United Kingdom

EU Contribution

€ 490 132

KRAEFTENS BEKAEMPELSE

Denmark

EU Contribution

€ 519 662,80

BREAST INTERNATIONAL GROUP - AISBL

Belgium

EU Contribution

€ 42 882,30

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 600 674,80

CENTRE ANTICANCEREUX LEON BERARD

France

EU Contribution

€ 136 884

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 170 906,40

CANCER COUNCIL VICTORIA

Australia

THE UNIVERSITY OF WARWICK

United Kingdom

EU Contribution

€ 319 872

Project information

Grant agreement ID: 223175

Status

Closed project

  • Start date

    1 May 2009

  • End date

    31 January 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 703 903,20

  • EU contribution

    € 11 715 501

Coordinated by:

KAROLINSKA INSTITUTET

Sweden